Join Growin Stock Community!

Kodiak sciences inc.KOD.US Overview

US StockHealthcare
(No presentation for KOD)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

KOD AI Insights

KOD Overall Performance

KOD AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

KOD Recent Performance

-6.39%

Kodiak sciences inc.

-3.61%

Avg of Sector

-2.16%

S&P500

KOD PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

KOD Key Information

KOD Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

KOD Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Price of KOD

KOD FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

KOD Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.11
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
72.07
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.11
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
72.07
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is KOD's latest earnings report released?

    The most recent financial report for Kodiak sciences inc. (KOD) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating KOD's short-term business performance and financial health. For the latest updates on KOD's earnings releases, visit this page regularly.

  • How much debt does KOD have?

    As of the end of the reporting period, Kodiak sciences inc. (KOD) had total debt of 162.2M, with a debt ratio of 0.74. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does KOD have?

    At the end of the period, Kodiak sciences inc. (KOD) held Total Cash and Cash Equivalents of 78.22M, accounting for 0.36 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is KOD's EPS continuing to grow?

    According to the past four quarterly reports, Kodiak sciences inc. (KOD)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.16. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of KOD?

    Kodiak sciences inc. (KOD)'s Free Cash Flow (FCF) for the period is -32.94M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 54.21% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.